login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
OKYO PHARMA LTD (OKYO) Stock News
USA
- NASDAQ:OKYO -
GG00BMFG5F62
-
Common Stock
1.98
USD
-0.09 (-4.35%)
Last: 9/19/2025, 8:00:02 PM
2.1
USD
+0.12 (+6.06%)
After Hours:
9/19/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
OKYO Latest News, Press Relases and Analysis
All
Press Releases
2 months ago - By: OKYO Pharma LTD
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
2 months ago - By: OKYO Pharma LTD
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
2 months ago - By: Benzinga
- Mentions:
HBIO
SRPT
MEIP
WINT
...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
2 months ago - By: Benzinga
- Mentions:
SSY
SRPT
CUE
PDSB
...
12 Health Care Stocks Moving In Wednesday's After-Market Session
3 months ago - By: ACCESS Newswire
Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited
2 months ago - By: OKYO Pharma LTD
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
2 months ago - By: OKYO Pharma LTD
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
3 months ago - By: OKYO Pharma LTD
OKYO Pharma to Present at the Bio International Convention
3 months ago - By: OKYO Pharma LTD
OKYO Pharma to Present at the Bio International Convention
4 months ago - By: OKYO Pharma LTD
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
4 months ago - By: OKYO Pharma LTD
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
5 months ago - By: OKYO Pharma LTD
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
5 months ago - By: OKYO Pharma LTD
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
5 months ago - By: OKYO Pharma LTD
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
6 months ago - By: OKYO Pharma LTD
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
6 months ago - By: OKYO Pharma LTD
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
6 months ago - By: OKYO Pharma LTD
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
6 months ago - By: OKYO Pharma LTD
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
7 months ago - By: OKYO Pharma LTD
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
8 months ago - By: OKYO Pharma LTD
OKYO Pharma Announces Chairman and CEO Acquire Shares
8 months ago - By: OKYO Pharma LTD
OKYO Pharma Announces Chairman and CEO Acquire Shares
8 months ago - By: ACCESS Newswire
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
8 months ago - By: OKYO Pharma LTD
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
8 months ago - By: OKYO Pharma LTD
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
8 months ago - By: OKYO Pharma LTD
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
8 months ago - By: OKYO Pharma LTD
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
10 months ago - By: OKYO Pharma LTD
OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference
a year ago - By: OKYO Pharma LTD
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
a year ago - By: OKYO Pharma LTD
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
a year ago - By: OKYO Pharma LTD
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
a year ago - By: OKYO Pharma LTD
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
a year ago - By: OKYO Pharma LTD
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
a year ago - By: OKYO Pharma LTD
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
a year ago - By: OKYO Pharma LTD
OKYO Pharma Announces Chairman Acquires Shares
a year ago - By: OKYO Pharma LTD
OKYO Pharma Announces Chairman Acquires Shares
Please enable JavaScript to continue using this application.